Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: Demethylation of the miR-146a promoter by 5-Aza-2’-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer

Figure 5

Comparing the methylation levels of four CpG sites located in the miR-146a promoter collected from samples from the different group by direct BSP sequencing. (A) Representative genomic sequencing chromatograms of the miR-146a promoter for each group. DNA was first treated with sodium bisulfite, and the amplified PCR products were then directly subjected to sequencing. The upper sequence is the untreated miR-146a promoter sequence; the lower sequences are treated sequences in different groups. The open boxes indicate the CpG sites. (B) Percentages of the methylation of four CpG sites in the miR-146a promoter. The methylation percentage of the individual CpG sites was calculated by the peak height of methylated residues (cytosine, C) divided by the sum of methylated and unmethylated residues (thymine, T). The methylation rate (%) is represented as the average ratio of methylated cytosines to total cytosines (methylated plus unmethylated) of all samples in each group. The data are the mean ± SD, n = 4–6 mice per group. *P < 0.05 and **P < 0.01 compared to the controls.

Back to article page